Insider Trading March 19, 2026

DocuSign Growth Head Sells $803,042 in Shares as Company Posts Fiscal Q4 Beat

Robert Chatwani executed planned sales under a Rule 10b5-1 arrangement; DocuSign topped Q4 earnings and revenue estimates while analysts trimmed price targets

By Caleb Monroe DOCU
DocuSign Growth Head Sells $803,042 in Shares as Company Posts Fiscal Q4 Beat
DOCU

Robert Chatwani, President General Manager, Growth at DocuSign (DOCU), sold 17,492 shares on March 18, 2026, under a Rule 10b5-1 trading plan for total proceeds of about $803,042. DocuSign reported fiscal fourth-quarter 2026 EPS of $1.01 on revenue of $837 million, both above consensus. Multiple brokerages adjusted their price targets following the results.

Key Points

  • Insider sale: Robert Chatwani sold 17,492 DocuSign shares on March 18, 2026, for roughly $803,042 under a Rule 10b5-1 plan.
  • Earnings beat: DocuSign reported fiscal Q4 2026 EPS of $1.01 and revenue of $837 million, both above consensus estimates.
  • Analyst re-pricing: Multiple firms trimmed price targets - RBC to $55, UBS to $54, Piper Sandler to $52, and Citizens to $86 - reflecting mixed views on growth and margins; impacts are concentrated in enterprise software and cloud services sectors.

Transaction specifics

Robert Chatwani, who serves as President General Manager, Growth at DocuSign (NASDAQ: DOCU), sold 17,492 shares of the company’s common stock on March 18, 2026. The disposals were carried out in several transactions at prices ranging from $45.25 to $49.80 per share, producing aggregate proceeds of approximately $803,042. The trades were implemented under a Rule 10b5-1 trading plan.

Post-sale ownership and market moves

After these sales, Chatwani directly holds 72,458 shares of DocuSign. The company’s stock is trading at $47.75 at the time of the report, reflecting a decline of 44% over the past year and a 30% decline year-to-date.

Valuation note

InvestingPro’s analysis, cited in available reporting, indicates DocuSign appears undervalued on its Fair Value assessment. The platform is noted as providing detailed insights into the company’s financial position and growth prospects.

Quarterly results and analyst responses

DocuSign released fourth-quarter fiscal 2026 results showing earnings per share of $1.01, ahead of the $0.95 consensus estimate. Revenue in the quarter was $837 million, topping the $827.9 million expectation. Following the earnings beat, several analyst firms adjusted their price targets and reiterated or changed ratings.

RBC Capital lowered its price target to $55 from $70 while maintaining a Sector Perform rating, observing that fiscal 2027 guidance met or slightly exceeded expectations but that operating margin guidance was modestly below forecasts. UBS trimmed its target to $54 from $75 and kept a Neutral rating, citing concerns about the growth outlook. Piper Sandler reduced its target to $52 from $75, while emphasizing solid fourth-quarter results and potential growth in annual recurring revenue. Citizens cut its price target to $86 from $124 and maintained a Market Outperform rating, noting the company’s substantial customer base and market potential.

Context and implications

The insider sale, executed through a prearranged plan, coincides with reported outperformance in the most recent quarter and a series of analyst target revisions that reflect differing views on growth and margin trajectories. The market reaction to the company’s stock performance and analyst updates is evident in the year-over-year and year-to-date share-price declines noted above.


Note: The article reflects the transaction details, financial results, analyst actions, and valuation commentary available in the reported information. Where data or commentary was limited in scope, the piece does not infer additional causes or outcomes beyond what was provided.

Risks

  • Share-price volatility - the stock has fallen 44% over the past year and 30% year-to-date, posing market-risk for investors in enterprise software and cloud services.
  • Guidance and margin uncertainty - analysts noted fiscal 2027 operating margin guidance was modestly below expectations and some firms cited growth-outlook concerns, creating uncertainty for valuation and forecasts.
  • Analyst divergence - multiple price-target cuts highlight differing assessments of DocuSign’s near-term growth and long-term potential, which may lead to varied investor responses and trading activity.

More from Insider Trading

Klaviyo Director Executes $3.8M Sale, Converts Series A to Series B as Company Rolls Out $500M Buyback Mar 19, 2026 BFI Co. liquidates 19,980 Phibro Animal Health shares for about $1.19M under Rule 10b5-1 plan Mar 19, 2026 NextNav COO Sells $57K in Stock as Company Highlights Liquidity and PNT Progress Mar 19, 2026 Director Erik D. Ragatz Boosts Stake in Grocery Outlet with $486,382 Purchase Mar 19, 2026 Silvaco Group insider Pesic Illiya I. reduces holdings in two sales, later receives nominal stock award Mar 19, 2026